Annual EBITDA:
-$380.21M-$6.06M(-1.62%)Summary
- As of today, RLAY annual EBITDA is -$380.21 million, with the most recent change of -$6.06 million (-1.62%) on December 31, 2024.
- During the last 3 years, RLAY annual EBITDA has fallen by -$157.13 million (-70.44%).
- RLAY annual EBITDA is now -696.50% below its all-time high of -$47.73 million, reached on December 31, 2018.
Performance
RLAY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$79.64M-$3.80M(-5.01%)Summary
- As of today, RLAY quarterly EBITDA is -$79.64 million, with the most recent change of -$3.80 million (-5.01%) on September 30, 2025.
- Over the past year, RLAY quarterly EBITDA has increased by +$15.36 million (+16.17%).
- RLAY quarterly EBITDA is now -321.85% below its all-time high of $35.90 million, reached on December 31, 2020.
Performance
RLAY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$322.79M+$15.36M(+4.54%)Summary
- As of today, RLAY TTM EBITDA is -$322.79 million, with the most recent change of +$15.36 million (+4.54%) on September 30, 2025.
- Over the past year, RLAY TTM EBITDA has increased by +$66.66 million (+17.12%).
- RLAY TTM EBITDA is now -1951.44% below its all-time high of -$15.73 million, reached on March 31, 2019.
Performance
RLAY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RLAY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -1.6% | +16.2% | +17.1% |
| 3Y3 Years | -70.4% | +2.4% | -11.1% |
| 5Y5 Years | -368.2% | -123.1% | -185.3% |
RLAY EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -70.4% | at low | -8.5% | +28.1% | -11.1% | +17.1% |
| 5Y | 5-Year | -627.7% | at low | -321.9% | +28.1% | -517.8% | +17.1% |
| All-Time | All-Time | -696.5% | at low | -321.9% | +28.1% | -1951.4% | +17.1% |
RLAY EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$79.64M(-5.0%) | -$322.79M(+4.5%) |
| Jun 2025 | - | -$75.84M(+9.3%) | -$338.15M(+9.4%) |
| Mar 2025 | - | -$83.66M(-0.0%) | -$373.07M(+1.9%) |
| Dec 2024 | -$380.21M(-1.6%) | -$83.64M(+12.0%) | -$380.21M(+2.4%) |
| Sep 2024 | - | -$95.00M(+14.2%) | -$389.45M(-5.9%) |
| Jun 2024 | - | -$110.76M(-22.0%) | -$367.86M(-1.1%) |
| Mar 2024 | - | -$90.80M(+2.2%) | -$363.97M(+2.7%) |
| Dec 2023 | -$374.15M(-21.9%) | -$92.89M(-26.5%) | -$374.15M(-2.9%) |
| Sep 2023 | - | -$73.41M(+31.3%) | -$363.49M(+2.2%) |
| Jun 2023 | - | -$106.87M(-5.8%) | -$371.68M(-8.8%) |
| Mar 2023 | - | -$100.98M(-22.8%) | -$341.46M(-11.3%) |
| Dec 2022 | -$306.82M | -$82.23M(-0.8%) | -$306.82M(-5.6%) |
| Sep 2022 | - | -$81.60M(-6.4%) | -$290.45M(-8.9%) |
| Jun 2022 | - | -$76.66M(-15.5%) | -$266.83M(-8.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$66.34M(-0.7%) | -$247.01M(-11.2%) |
| Dec 2021 | -$223.08M(-327.0%) | -$65.85M(-13.6%) | -$222.16M(-84.5%) |
| Sep 2021 | - | -$57.98M(-2.0%) | -$120.41M(-22.7%) |
| Jun 2021 | - | -$56.84M(-37.0%) | -$98.12M(-44.0%) |
| Mar 2021 | - | -$41.49M(-215.6%) | -$68.13M(-30.4%) |
| Dec 2020 | -$52.25M(+35.7%) | $35.90M(+200.6%) | -$52.25M(+53.8%) |
| Sep 2020 | - | -$35.69M(-32.9%) | -$113.13M(-14.6%) |
| Jun 2020 | - | -$26.85M(-4.9%) | -$98.71M(-8.4%) |
| Mar 2020 | - | -$25.60M(-2.5%) | -$91.07M(-12.1%) |
| Dec 2019 | -$81.20M(-70.1%) | -$24.98M(-17.4%) | -$81.20M(-44.4%) |
| Sep 2019 | - | -$21.27M(-10.7%) | -$56.22M(-60.9%) |
| Jun 2019 | - | -$19.21M(-22.1%) | -$34.95M(-122.1%) |
| Mar 2019 | - | -$15.73M | -$15.73M |
| Dec 2018 | -$47.73M | - | - |
FAQ
- What is Relay Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Relay Therapeutics, Inc.?
- What is Relay Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Relay Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Relay Therapeutics, Inc.?
- What is Relay Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Relay Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Relay Therapeutics, Inc.?
- What is Relay Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Relay Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of RLAY is -$380.21M
What is the all-time high annual EBITDA for Relay Therapeutics, Inc.?
Relay Therapeutics, Inc. all-time high annual EBITDA is -$47.73M
What is Relay Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, RLAY annual EBITDA has changed by -$6.06M (-1.62%)
What is Relay Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of RLAY is -$79.64M
What is the all-time high quarterly EBITDA for Relay Therapeutics, Inc.?
Relay Therapeutics, Inc. all-time high quarterly EBITDA is $35.90M
What is Relay Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, RLAY quarterly EBITDA has changed by +$15.36M (+16.17%)
What is Relay Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of RLAY is -$322.79M
What is the all-time high TTM EBITDA for Relay Therapeutics, Inc.?
Relay Therapeutics, Inc. all-time high TTM EBITDA is -$15.73M
What is Relay Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, RLAY TTM EBITDA has changed by +$66.66M (+17.12%)